Polaris Pharmaceuticals (6550): Correction Announcement Regarding Director Shareholding Disclosure
Polaris Pharmaceuticals has announced a correction regarding the shareholding of Director Chen Hsien-Che during the 115th fiscal year director election, adjusting the figure from 49.5 million shares to 4.95 million shares.
📋 Article Processing Timeline
- 📰 Published: May 22, 2026 at 06:31
- 🔍 Collected: May 22, 2026 at 06:31 (0 min after Published)
- 🤖 AI Analyzed: May 22, 2026 at 07:10 (38 min after Collected)
Announcement Date: 115/05/21
Company Code: 6550
Company Name: Polaris Pharmaceuticals
Subject: Correction of shareholding numbers during the 115th director election
Explanation:
1. Date of incident: 115/05/21
2. Company name: Polaris Pharmaceuticals Group Co., Ltd.
3. Relationship to company: The Company
4. Cross-shareholding ratio: Not applicable
5. Reason for occurrence: Correction of shareholding during 115th director election
6. Information item corrected: Shareholding numbers during director election
7. Amount/Content before correction: Director Chen Hsien-Che: 49,500,000 shares
8. Amount/Content after correction: Director Chen Hsien-Che: 4,950,000 shares
9. Measures taken: Uploaded to the Market Observation Post System after correction.
10. Other matters: None
Company Code: 6550
Company Name: Polaris Pharmaceuticals
Subject: Correction of shareholding numbers during the 115th director election
Explanation:
1. Date of incident: 115/05/21
2. Company name: Polaris Pharmaceuticals Group Co., Ltd.
3. Relationship to company: The Company
4. Cross-shareholding ratio: Not applicable
5. Reason for occurrence: Correction of shareholding during 115th director election
6. Information item corrected: Shareholding numbers during director election
7. Amount/Content before correction: Director Chen Hsien-Che: 49,500,000 shares
8. Amount/Content after correction: Director Chen Hsien-Che: 4,950,000 shares
9. Measures taken: Uploaded to the Market Observation Post System after correction.
10. Other matters: None
FAQ
北極星藥業-KYが発表した訂正公告の内容は何ですか？
115年度の取締役選任時における取締役陳賢哲氏の持株数に誤りがあり、その数値を訂正しました。
陳賢哲取締役の持株数はどう訂正されましたか？
訂正前は4,950万株とされていましたが、正しくは495万株に訂正されました。
事実発生日はいつですか？
2026年（民国115年）5月21日です。
この件に関する対応は完了していますか？
はい。訂正された情報は、台湾の公開資訊観測站に再アップロード済みです。
北極星藥業-KYの会社代号は何ですか？
台湾証券取引所における会社代号は6550です。